Fmoc-D-Asp(OtBu)-OHCAS# 12883-39-3 |
- PF-4708671
Catalog No.:BCC5031
CAS No.:1255517-76-0
- BIX 02565
Catalog No.:BCC4303
CAS No.:1311367-27-7
- BI-D1870
Catalog No.:BCC5030
CAS No.:501437-28-1
- CMK
Catalog No.:BCC1489
CAS No.:821794-90-5
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 12883-39-3 | SDF | Download SDF |
| PubChem ID | 7019703 | Appearance | Powder |
| Formula | C23H25NO6 | M.Wt | 411.5 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | (3R)-3-(9H-fluoren-9-ylmethoxycarbonylamino)-4-[(2-methylpropan-2-yl)oxy]-4-oxobutanoic acid | ||
| SMILES | CC(C)(C)OC(=O)C(CC(=O)O)NC(=O)OCC1C2=CC=CC=C2C3=CC=CC=C13 | ||
| Standard InChIKey | VZXQYACYLGRQJU-LJQANCHMSA-N | ||
| Standard InChI | InChI=1S/C23H25NO6/c1-23(2,3)30-21(27)19(12-20(25)26)24-22(28)29-13-18-16-10-6-4-8-14(16)15-9-5-7-11-17(15)18/h4-11,18-19H,12-13H2,1-3H3,(H,24,28)(H,25,26)/t19-/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Fmoc-D-Asp(OtBu)-OH Dilution Calculator
Fmoc-D-Asp(OtBu)-OH Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.4301 mL | 12.1507 mL | 24.3013 mL | 48.6027 mL | 60.7533 mL |
| 5 mM | 0.486 mL | 2.4301 mL | 4.8603 mL | 9.7205 mL | 12.1507 mL |
| 10 mM | 0.243 mL | 1.2151 mL | 2.4301 mL | 4.8603 mL | 6.0753 mL |
| 50 mM | 0.0486 mL | 0.243 mL | 0.486 mL | 0.9721 mL | 1.2151 mL |
| 100 mM | 0.0243 mL | 0.1215 mL | 0.243 mL | 0.486 mL | 0.6075 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Fmoc-D-Asp(OtBu)-OH
- Mycophenolate Mofetil
Catalog No.:BCC2290
CAS No.:128794-94-5
- Kalopanaxsaponin H
Catalog No.:BCN2572
CAS No.:128730-82-5
- Eucamalduside A
Catalog No.:BCN7321
CAS No.:1287220-29-4
- FRAX597
Catalog No.:BCC4172
CAS No.:1286739-19-2
- 1,6-O,O-Diacetylbritannilactone
Catalog No.:BCN7792
CAS No.:1286694-67-4
- PyBOP
Catalog No.:BCC2820
CAS No.:128625-52-5
- Z(2-Br)-Osu
Catalog No.:BCC2806
CAS No.:128611-93-8
- Ospemifene
Catalog No.:BCC5557
CAS No.:128607-22-7
- Pingpeimine C
Catalog No.:BCN8411
CAS No.:128585-96-6
- ML167
Catalog No.:BCC5348
CAS No.:1285702-20-6
- GSK2578215A
Catalog No.:BCC6243
CAS No.:1285515-21-0
- Romidepsin (FK228, depsipeptide)
Catalog No.:BCC3597
CAS No.:128517-07-7
- Fargesol
Catalog No.:BCN6421
CAS No.:128855-64-1
- Maohuoside A
Catalog No.:BCN5348
CAS No.:128988-55-6
- Suramin hexasodium salt
Catalog No.:BCC7079
CAS No.:129-46-4
- Methysergide maleate
Catalog No.:BCC5698
CAS No.:129-49-7
- SP 600125
Catalog No.:BCC2474
CAS No.:129-56-6
- Buclizine HCl
Catalog No.:BCC4516
CAS No.:129-74-8
- Rivastigmine Tartrate
Catalog No.:BCC3851
CAS No.:129101-54-8
- Evodosin A
Catalog No.:BCN7322
CAS No.:1291053-38-7
- ENMD-2076 L-(+)-Tartaric acid
Catalog No.:BCC2185
CAS No.:1291074-87-7
- CGRP 8-37 (rat)
Catalog No.:BCC5717
CAS No.:129121-73-9
- 2-(2,2-Dimethyl-1,3-dioxolan-4-yl)propane-1,2-diol
Catalog No.:BCC8475
CAS No.:129141-48-6
- Gancaonin M
Catalog No.:BCN4757
CAS No.:129145-51-3
Solid-Phase Total Synthesis of Bacitracin A.[Pubmed:11667271]
J Org Chem. 1996 Jun 14;61(12):3983-3986.
An efficient solid-phase method for the total synthesis of bacitracin A is reported. This work was undertaken in order to provide a general means of probing the intriguing mode of action of the bacitracins and exploring their potential for use against emerging drug-resistant pathogens. The synthetic approach to bacitracin A involves three key features: (1) linkage to the solid support through the side chain of the L-asparaginyl residue at position 12 (L-Asn(12)), (2) cyclization through amide bond formation between the alpha-carboxyl of L-Asn(12) and the side chain amino group of L-Lys(8), and (3) postcyclization addition of the N-terminal thiazoline dipeptide as a single unit. To initiate the synthesis, Fmoc L-Asp(OH)-OAllyl was attached to a PAL resin. The chain of bacitracin A was elaborated in the C-to-N direction by sequential piperidine deprotection/HBTU-mediated coupling cycles with Fmoc D-Asp(OtBu)-OH, Fmoc L-His(Trt)-OH, Fmoc D-Phe-OH, Fmoc L-Ile-OH, Fmoc D-Orn(Boc)-OH, Fmoc L-Lys(Aloc)-OH, Fmoc L-Ile-OH, Fmoc D-Glu(OtBu)-OH, and Fmoc L-Leu-OH. The allyl ester and allyl carbamate protecting groups of L-Asn(12) and L-Lys(8), respectively, were simultaneously and selectively removed by treating the peptide-resin with palladium tetrakis(triphenylphosphine), acetic acid, and triethylamine. Cyclization was effected by PyBOP/HOBT under the pseudo high-dilution conditions afforded by attachment to the solid support. After removal of the N-terminal Fmoc group, the cyclized peptide was coupled with 2-[1'(S)-(tert-butyloxycarbonylamino)-2'(R)-methylbutyl]-4(R)-carboxy-Delta(2)-th iazoline (1). The synthetic peptide was deprotected and cleaved from the solid support under acidic conditions and then purified by reverse-phase HPLC. The synthetic material exhibited an ion in the FAB-MS at m/z 1422.7, consistent with the molecular weight calculated for the parent ion of bacitracin A (MH(+) = C(73)H(84)N(10)O(23)Cl(2), 1422.7 g/mol). It was also indistinguishable from authentic bacitracin A by high-field (1)H NMR and displayed antibacterial activity equal to that of the natural product, thus confirming its identity as bacitracin A. The overall yield for the solid-phase synthesis was 24%.
